[Pulmonary arterial hypertension. New therapeutic principles improve treatment of a rare condition].
Ekmehag
Björn
B
Universitetssjukhuset i Lund. bjorn.ekmehag@skane.se
D000959:Antihypertensive Agents / Q000627:therapeutic use; D018450:Disease Progression; D065130:Endothelin A Receptor Antagonists; D011464:Epoprostenol / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D016040:Lung Transplantation; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011379:Prognosis; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D065130:Endothelin A Receptor Antagonists; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors; D011464:Epoprostenol